CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Neon Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Neon Therapeutics Inc
40 Erie Street
Suite 110
Phone: (617) 337-4701p:617 337-4701 Cambridge, MA  02139-4254  United States Fax: (302) 655-5049f:302 655-5049
This company was Merged or Acquired on 5/6/2020.
This company ceased filing statements with the SEC on 5/18/2020.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Neon Therapeutics is a clinical-stage immuno-oncology company. The Company is focused on developing therapeutics leveraging neoantigen biology to treat cancer. The Company's neoantigen-based product engine allows it to develop multiple treatment modalities, including vaccines and thymus (T) cell therapies targeting both personalized and shared neoantigens. The Company's neoantigen-based product engine targets both neoantigens that are specific to individual patients, as well as neoantigens that are shared across patients and tumor types. The Company's NEO-PV-01 program is a personalized neoantigen vaccine. NEO-PV-01 utilizes an epitope computational engine called Real-time Epitope Computation for Oncology (RECON). The Company's NEO-PTC-01 is an Adoptive T Cell Therapy. NEO-PTC-01 uses immunogens in co-culture with T cells and monocyte-derived dendritic cells from patients in order to ex vivo stimulate autologous T cells to respond against neoantigen targets.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202012/31/2019YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Director, President and Chief Executive Officer HughO'Dowd
Chief Executive Officer HughO’Dowd
Chairman of the Board Cary G.Pfeffer 56 1/1/2016
23 additional Officers and Directors records available in full report.

Business Names
Business Name
Neon Securities Corporation
NTGN
Onco3, Inc.

General Information
Number of Employees: 71 (As of 12/31/2019)
Outstanding Shares: 28,966,658 (As of 4/30/2020)
Shareholders: 35
Stock Exchange: NASD
Federal Tax Id: 463915846
Fax Number: (302) 655-5049
Email Address: info@neontherapeutics.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 31, 2023